141 related articles for article (PubMed ID: 21999120)
1. Raltitrexed in mesothelioma.
Surmont VF; van Meerbeeck JP
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1481-90. PubMed ID: 21999120
[TBL] [Abstract][Full Text] [Related]
2. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
4. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study.
Bottomley A; Gaafar R; Manegold C; Burgers S; Coens C; Legrand C; Vincent M; Giaccone G; Van Meerbeeck J; ;
J Clin Oncol; 2006 Mar; 24(9):1435-42. PubMed ID: 16446322
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
Tomek S; Manegold C
Lung Cancer; 2004 Aug; 45 Suppl 1():S103-19. PubMed ID: 15261443
[TBL] [Abstract][Full Text] [Related]
6. Current concepts in chemotherapy for malignant pleural mesothelioma.
Sørensen JB
Clin Respir J; 2008 Apr; 2(2):74-9. PubMed ID: 20298310
[TBL] [Abstract][Full Text] [Related]
7. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
Bottomley A; Coens C; Efficace F; Gaafar R; Manegold C; Burgers S; Vincent M; Legrand C; van Meerbeeck JP;
J Clin Oncol; 2007 Dec; 25(36):5770-6. PubMed ID: 18089874
[TBL] [Abstract][Full Text] [Related]
8. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
Budde LS; Hanna NH
Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
[TBL] [Abstract][Full Text] [Related]
10. Raltitrexed: current clinical status and future directions.
Van Cutsem E; Cunningham D; Maroun J; Cervantes A; Glimelius B
Ann Oncol; 2002 Apr; 13(4):513-22. PubMed ID: 12056700
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K; John WJ; Vogelzang NJ
Semin Oncol; 2002 Feb; 29(1):77-81. PubMed ID: 11836672
[TBL] [Abstract][Full Text] [Related]
12. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
[TBL] [Abstract][Full Text] [Related]
13. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
15. Raltitrexed: optimism and reality.
Wilson KS; Malfair Taylor SC
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
[TBL] [Abstract][Full Text] [Related]
16. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
17. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
Hanauske AR
Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
[TBL] [Abstract][Full Text] [Related]
18. [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
Sato A; Kurihara M; Matsukawa M; Yamazaki T; Shimada K; Endo W; Yamazaki T; Nakamachi M
Gan To Kagaku Ryoho; 2000 Apr; 27(4):617-21. PubMed ID: 10791007
[TBL] [Abstract][Full Text] [Related]
19. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).
Baas P; Ardizzoni A; Grossi F; Nackaerts K; Numico G; Van Marck E; van de Vijver M; Monetti F; Smid-Geirnaerdt MJ; van Zandwijk N; Debruyne C; Legrand C; Giaccone G;
Eur J Cancer; 2003 Feb; 39(3):353-7. PubMed ID: 12565988
[TBL] [Abstract][Full Text] [Related]
20. Raltitrexed and pemetrexed studies in mesothelioma have not shown improved quality of life nor prolonged survival compared with effective pleurodesis with thoracoscopic talc poudrage.
Aelony Y
J Clin Oncol; 2006 Oct; 24(28):4667; author reply 4667-8. PubMed ID: 17008709
[No Abstract] [Full Text] [Related]
[Next] [New Search]